Eli Lilly bets $135M on neuro biotech Disarm Therapeutics, with up to $1.2B to come Vertex's big move beyond cystic fibrosis hits a wall with lung drug failure Sage shares data on retreatment with depression drug zuranolone Otsuka's guadecitabine flunks 2 more late-phase cancer trials Dewpoint, fresh off a $77M round, snags former Sanofi CMO as its new chief COVID-19 mRNA vaccine candidate from Sanofi and Translate protects mice, monkeys: study Regeneron, in the thick of COVID-19 fight, snags historic FDA approval for Ebola treatment Featured Story | By Amirah Al Idrus Eli Lilly is snapping up Disarm Therapeutics, a biotech working to “disarm” the SARM1 protein, which plays a key role in neurodegeneration. The deal is worth $135 million upfront but Disarm investors could reap as much as $1.225 billion down the line if Lilly translates its preclinical work to marketed products. read more |
| |
|---|
|
| | In our recent 90 Second Insight video, WCG ThreeWire's Molly Hair, Director of Site Engagement and Management, discusses how study staffing shortages due to COVID-19 are affecting clinical research in oncology. Visit wcgclinical.com to see how our Site Support and Augmentation Services can get your oncology trial back on track. |
Top Stories By Amirah Al Idrus Vertex is pulling the plug on a treatment for a rare, inherited lung disease after the prospect caused abnormally high levels of liver enzymes in a phase 2 study. The company will continue developing a “structurally distinct drug” for the same disorder. read more By Nick Paul Taylor Sage Therapeutics has shared data from an open-label trial of zuranolone as it starts to remake the case for the drug following its phase 3 failure. The study found around half of major depressive disorder patients who respond to zuranolone require retreatment and that outcomes for subsequent courses are comparable to the initial treatment. read more By Nick Paul Taylor Otsuka’s guadecitabine has failed to improve overall survival in two phase 3 blood cancer clinical trials. Guadecitabine has now failed three late-phase trials, leaving Otsuka to weigh up the next steps for a hypomethylating agent it acquired in its $886 million takeover of Astex Pharmaceuticals. read more By Amirah Al Idrus In February, Sanofi CEO Paul Hudson cut four top executives as part of a bid to simplify the company’s management structure. Among them was Ameet Nathwani, M.D., its chief medical officer and chief digital officer, who—like many a colleague before him—made the leap from Big Pharma to small biotech. read more By Arlene Weintraub Sanofi and its partner Translate Bio tested their mRNA COVID-19 vaccine candidate MRT5500 in mice and macaques and found that the animals developed neutralizing antibodies and a favorable T-cell response, they reported. A phase 1/2 trial is expected to start this quarter. read more By Eric Sagonowsky With the world focused on the fight against COVID-19, the scientific community just scored a big win in another infectious disease. The FDA approved the first treatment—Inmazeb from Regeneron—to treat Ebola in adults and children. read more | | Experts in our field with 20+ yrs. experience in Viral Vector & Plasmid DNA (R&D, High Quality, GMP) manufacture for pre-clinical to commercial supply. Now part of the Cognate BioServices family, Cobra has rebranded – look around our updated website. Learn more. |
Resources Sponsored By: Elligo Health Research® Understanding the Challenges COVID-19 Pediatric Clinical Trials Face | White Paper Sponsored By: ICON Clinical Research Ltd The culture of clinical research is evolving from one directed by researchers to one driven by the needs of patients and those who care for them. Sponsored By: The PerkinElmer Signals Screening Team Creating integrated HCS workflows in a single platform increases accuracy; reduces time and helps to identify the most appropriate hits or drug candidates. Learn more about a reliable method for creating a more efficient, faster, 3D image and multi-parametric data analysis workflow. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Cascade Chemistry, API CDMO Struggling with complex chemistry to get APIs for clinical trials? Find out what to look for in an API CDMO partner to gain expertise and speed that lead to success. Sponsored by: EVERSANA An integrated compliance model can be the competitive differentiator to commercialization and move the needle from cost center to value. Learn How. Sponsored by: Catalent Learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools. Sponsored by: Catalent This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. Sponsored by: Formedix Learn how to save time and reduce costs and complexity by streamlining the clinical trial process. Sponsored by: LabVantage Want to leapfrog lengthy LIMS deployments and position your pharmaceutical lab for success? Find out how with LabVantage Solutions. Sponsored by: Thermo Fisher Scientific Learn how to safeguard supply, improve distribution and reduce program costs and risks Sponsored by: Clinical Ink Learn how the right data capture solution can prompt the patient to follow the correct procedures and automatically sort the responses, according to protocol. Sponsored by: Guidehouse While COVID-19 has shifted the rules of the healthcare industry, research shows there was already progress on changes being made for how pharma companies are launching products. Sponsored by: Blue Matter Consulting Senior executives from 16 biopharma companies share their thoughts on how COVID-19 will change how the industry engages with its customers. A complete Life Science Industry Snapshot in One Report Sponsored by: Evidation Health Achieving patient centricity depends on evolving how evidence is generated. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: 4G Clinical This white paper addresses the complexity of basket and umbrella designs, and how modern technology is critical to run flexible, agile and quality-driven trials. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Medtech Innovation Week October 19-22 Drug Development Immersion: Live, Online Course October 21-22, 2020 | 9am - 3:30pm ET Become Fluent In Drug Development With Our Industry Expert October 21-22, 2020 | 9am - 3:30pm ET Learn How To Bring A Drug Successfully To Market Oct 21-22, 2020 | Live, Online BioBasics 101: The Biology of Biotech for the Non-Scientist: Live, Online Course November 12-13, 2020 | 9am - 3:30pm ET Drug Development Boot Camp® VIRTUAL 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now | Due to COVID19 provisions – training will be conducted VIRTUALLY | Same excellent total immersion training in new medicine development will be made available to experts who want to make a difference to patients. | 